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REVIEW ARTICLE

Genetic Testing of Epileptic
Encephalopathies of Infancy: An
Approach
Suvasini Sharma, Asuri N. Prasad

ABSTRACT: the epileptic encephalopathies of infancy are a group of disorders characterized by intractable seizures, persistent
abnormality of cortical function documented on eeG, and consequently impaired neuro-developmental outcomes. the etiologies vary
and include; structural brain malformations, acquired brain insults, and inborn errors of metabolism in the majority of the affected
patients. In a proportion of these cases no obvious etiology is identifiable on investigation. Recent advances in molecular diagnostics
have led to the discovery of a number of gene defects that may be causal in many epileptic encephalopathies. Identification of the
causative mutation is important for prognostic and genetic counseling, and may also carry treatment implications. the recently described
genes include; Cyclin-Dependent Kinase-Like 5 gene (CDKL5), Protocadherin 19 (PCDH19), Sodium channel neuronal type 1a subunit
gene (SCN1A), Aristaless-Related Homeobox Gene (ARX), and Syntaxin binding protein 1 gene (STXBP1), amongst others. Distinct
electro-clinical syndromes are increasingly being identified amongst patients carrying the various mutations. In this review, we outline
the approach to clinical evaluation and genetic testing of epileptic encephalopathies in infancy.
RÉSUMÉ: Démarche concernant les tests génétiques pour les encéphalopathies épileptiques de la petite enfance. Les encéphalopathies
épileptiques de la petite enfance sont un groupe de maladies caractérisées par des crises convulsives réfractaires au traitement médical et des anomalies
de la fonction corticale persistantes, documentées par l'ÉeG, avec comme conséquence des troubles du développement neurologique. Leur étiologie est
variable : malformations cérébrales structurales, lésions cérébrales acquises et erreurs innées du métabolisme chez la plupart des patients. Chez une
certaine proportion des patients, la recherche d'une étiologie identifiable demeure vaine. Des progrès récents dans le domaine du diagnostique
moléculaire ont permi de découvrir un certain nombre de défauts génétiques qui peuvent être en cause dans plusieurs encéphalopathies épileptiques.
L'identification de la mutation causale est importante pour le pronostic et le conseil génétique et peut également avoir une incidence sur le traitement.
voici quelques uns des gènes décrits récemment : CDKL5, PCDH19, SCN1A, ARX et StXbP1. Des syndromes électro-cliniques distincts sont de plus
en plus identifiés chez les patients porteurs de différentes mutations. Dans cette revue, nous exposons brièvement comment aborder l'évaluation clinique
et génétique des encéphalopathies épileptiques de la petite enfance.
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epileptic encephalopathies are disorders in which the
combination of frequent and severe seizures along with the
unremitting interictal paroxysmal epileptiform activity
contributes to progressive neurological deterioration1. Several
epileptic encephalopathies have been described in infancy based
on their electroclinical features [age of onset, seizure type, and
electroencephalogram (eeG) pattern]. these include; Ohtahara
syndrome, early myoclonic encephalopathy, epilepsy of infancy
with migrating focal seizures, West syndrome, and Dravet
syndrome.
the etiologies of epileptic encephalopathies are
heterogeneous and a significant proportion of cases are
attributable to structural brain defects and inherited metabolic
disorders. However, in several instances of an epileptic
encephalopathy a pathogenic gene mutation has been identified
even when no clear genetic inheritance patterns or consanguinity
exist. As this is an evolving field, the genotype-phenotype
correlations are not well understood, and there is considerable
phenotypic variability within the same genetic defect; e.g.
mutations in the sodium channel genes cause Dravet syndrome,
as well as generalized epilepsy with febrile seizure plus. A
particular electroclinical syndrome may be caused by multiple
10
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genetic defects. For example, Ohtahara syndrome may be caused
by mutations in syntaxin binding protein-1 (STXBP-1)2,
Aristaless related homeobox (ARX)3, and Solute carrier family
25 member 22 (SLC25A22) gene encoding a mitochondrial
glutamate carrier4.
During the evaluation of a child with an epileptic
encephalopathy when no apparent cause is obvious on the basis
of an initial clinical evaluation, normal neuroimaging and
negative results on metabolic screening, other genetic etiologies
need to be considered. Identification of a specific gene defect
carries significant benefits, namely in providing genetic
counseling, and avoiding the delays, costs and inconvenience of
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invasive investigations such as liver, muscle and skin biopsies
which are often resorted to in such instances5. Such information
can influence the choice of anti-epileptic treatments. A
confirmed diagnosis will provide an answer to parents who may
have attributed the epileptic encephalopathy to another
incidental factor such as immunization, and even closure when
the condition is fatal6. Furthermore, the discovery of the
molecular genetic basis in addition aids understanding of
pathophysiological mechanisms and pathways in the different
epileptic encephalopathies.
In this article, we outline the approach to the genetic testing
of an infant with epileptic encephalopathies and emphasize the
clinical aspects that guide the clinician towards the appropriate
test.
Epileptic encephalopathies in infants

the electroencephalographic findings in infants with
epileptic encephalopathies are known to have an age-dependent
expression, depending on the degree of brain maturation7. For
example, the eeG may show a burst-suppression pattern in the
neonatal period, hypsarrhythmia in infancy, and evolution to
multifocal or generalized slow spike-wave discharges in early
childhood with poor organization of background rhythms. the

electro-clinical features of the common infantile epileptic
encephalopathies are summarized in table 1. the etiology may
be known (brain malformations, acquired brain insults,
chromosomal abnormalities, inherited metabolic disorders,
neurocutaneous syndromes such as tuberous sclerosis) or
cryptogenic.

Neonatal epileptic encephalopathies with burst suppression

In newborns, two syndromes are well characterized: early
myoclonic encephalopathy (eMe) and Ohtahara syndrome (also
called early infantile epileptic encephalopathy)8. both are
characterized by a burst suppression pattern on eeG. early
myoclonic encephalopathy typically presents in the first few
days of life. these infants have mixed seizures; erratic or
fragmentary myoclonus, focal seizures, and tonic seizures8. the
eeG shows a burst suppression pattern that is prominent during
sleep, but may disappear in the awake state. Frequently
encountered in this setting are inherited metabolic disorders
including; non-ketotic hyperglycinemia, organic acidemias,
Menke’s disease, Zellweger syndrome, and molybdenum
cofactor deficiency9. Pyridoxine dependency has also been
described as an etiology10. there are no known causative genes
at present.

Table 1: Electro-clinical characteristics and etiologies of epileptic encephalopathies in infancy
Epilepsy
syndrome

Age at onset

Seizure type

EEG findings

Etiology

Early myoclonic
encephalopathy

First few days
or weeks of
life

Erratic myoclonus,
focal seizures, and
tonic seizures

Burst suppression
pattern,
predominantly in
sleep

Inherited metabolic disorders (NKH,
organic acidemias, Menke’s disease,
Zellweger syndrome, molybdenum
cofactor deficiency, Pyridoxine
dependency

Ohtahara
syndrome

First few days
or weeks of
life

Tonic spasms, either
singly or in clusters,
Focal seizures

Burst suppression
pattern both in sleep
and wake states

Brain malformations such as cortical
dyspasia, hemimegalencephaly, and
Aicardi syndrome

STXBP-1, ARX,
SLC25A22

Epilepsy of
infancy with
migrating focal
seizures

First few days
or weeks of
life

Focal seizures arising
independently from
both hemispheres

Interictal multifocal
discharges, migrating
ictal paroxysmal
rhythms

Unknown; suspected genetic

SCN1A, PLCB1

West syndrome

3-12 months

Infantile spasms

Hypsarrhythmia

Perinatal brain injury, intra-uterine
infections, inherited metabolic
disorders, neurocutanoeous
syndromes, brain malformations,
post-natal acquired brain insults

CDKL-5, ARX,
STXBP-1, PLCB1

Dravet syndrome

First year of
life

Initially generalized
or partial seizures
with fever, Later,
myoclonus, atypical
absences and partial
seizures are noted.

Initially normal, later
generalized spike
wave and polyspike
wave discharges.

Genetic

SCN1A, PCDH 19,
GABRG2, SCN1B

Associated Genetic
etiologies

ARX: Aristaless-Related Homeobox Gene, CDKL-5: Cyclin-Dependent Kinase-Like 5 gene, SLC25A22: Solute carrier family
25 member 22 gene, STXBP1: Syntaxin binding protein 1 gene, SCN1A: Sodium channel neuronal type 1a subunit gene,
PCDH19: Protocadherin 19 gene, PLCB1: phospholipase C-β1 gene, SCN1B: Sodium channel neuronal type 1β subunit gene,
GABRG2: gamma aminobutyric acid type A receptor gamma 2 subunit gene
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Ohtahara syndrome typically has an onset within the first few
days or weeks of life with predominant tonic spasms, that may
be single, or occur in clusters. these occur both in sleep and
waking states. Focal seizures also occur in one third to one half
of the patients9. the eeG shows a burst suppression pattern that
is persistent across sleep-wake cycles. the most frequently
reported associations are brain malformations such as focal
cortical dysplasia, hemimegalencephaly, and Aicardi
syndrome11. Other gene defects that have been identified in these
patients include; mutations in the syntaxin binding protein-1
(STXBP-1)2, Aristaless related homeobox (ARX)3, and
SLC25A22 gene encoding a mitochondrial glutamate carrier4.
A similar epileptic encephalopathy attributable to mutations
in the potassium channel KCNQ2 gene that encodes the voltage
gated potassium channel Kv7.2 has been recently described12.
these infants experienced intractable seizures in the first week of
life with a prominent tonic component. Seizures generally
resolved by age three years but the children were left with
severe, intellectual disability and motor impairment. the eeG at
onset showed a burst-suppression pattern or multifocal
epileptiform activity. early magnetic resonance imaging (MRI)
of the brain showed characteristic hyperintensities in the basal
ganglia and thalamus that later resolved12. though the condition
appears similar to Ohtahara syndrome, subtle differences
include; progression with reduction in seizure frequency in
KCNQ2 encephalopathy in comparison to Ohtahara syndrome
which frequently evolves to West syndrome, and the unusual
occurrence of transient basal ganglia imaging abnormalities in
KCNQ2 encephalopathy.

Epilepsy of infancy with migrating focal seizures (Formerly
called malignant migrating partial seizures of infancy)

this condition is characterized by normal early development,
refractory focal seizures arising independently from both
hemispheres and severe psychomotor retardation and a poor
prognosis13. Mutations in the SCN1A gene encoding the alpha-1
subunit of the sodium channel were found in 2 out of 15 patients
with this condition in a recent study14. Freilich et al have also
reported a case of epilepsy of infancy with focal migrating
seizures with a novel SCN1A mutation15. Recently, a
homozygous deletion in the phospholipase C β 1 (PCB1) gene
has also been described in a child with this epilepsy syndrome16.
West syndrome

West syndrome is characterized by the occurrence of infantile
spasms, eeG finding of hypsarrhythmia, and developmental
delay or regression17. Infantile spasms typically occur between 3
to 12 months-of-age. Spasms usually occur in clusters
comprising of tonic contractions of limb and axial muscles, and
may be flexor, extensor or mixed. the spasms typically occur in
relation to the sleep wake cycle; they occur when the child wakes
up from sleep, or is going to sleep. the etiology is diverse. Any
insult to the developing brain (perinatal brain insult, intra-uterine
infections, inherited metabolic disorders, neurocutaneous
syndromes, brain malformations, post-natal acquired brain
insults (e.g. meningoencephalitis, hypoxic brain injury) during a
critical vulnerable time window can lead to West syndrome. In as
many as 30% of the affected children, no cause can be identified,
and in these cases pathogenic gene mutations are now being
12
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shown to play a causal role. Gene defects which have been
associated with West syndrome include cyclin dependent kinase5 like gene (CDKL-5) mutations18, ARX19, STXBP-120, SPTAN1
encoding α-II spectrin21, and phospholipase C-β1 mutations22.
Dravet syndrome

Dravet syndrome is characterized by the occurrence of
generalized or unilateral clonic or tonic–clonic seizures, usually
triggered by fever, in the first year of life of a previously normal
infant23. Later, other types of seizures are reported, including
myoclonus, atypical absences and partial seizures. early
development is normal and slows in the second year of life.
Cognitive decline and behavioral disturbances are frequently
noted.
Neurological signs consisting of hypotonia, ataxia, pyramidal
signs, and motor in- coordination may also be seen. A positive
family history is noted in 25% -71% of patients23. the inter-ictal
eeG is usually normal in the first year of life. between the
second and the fifth years of life, a progressive increase in
paroxysmal epileptiform abnormalities with background
slowing is evident in more than 50% of the cases on the eeG24.
Paroxysmal eeG abnormalities are constituted by generalized
spike wave and polyspike wave discharges. Focal and multifocal
abnormalities such as fast spikes or polyspikes are also
described. Mutations in the SCN1A gene encoding the alpha-1
subunit of the sodium channel are detectable in 70-80% of
patients with Dravet syndrome25. Rarely mutations have been
identified in the gamma aminobutyric acid type A receptor
gamma 2 subunit gene (GABARG2) and Sodium channel
neuronal type 1β subunit gene (SCN1B) genes25. the most
significant aspect of the molecular genetic basis is that most of
these mutations occur de novo, and the absence of a family
history or a Mendelian pattern of inheritance is not a necessary
prerequisite for testing25.
Mutations associated with PCDH19 (Protocadherin 19 gene)
have also been associated with a Dravet-like syndrome in girls26.
Mutations of PCDH19 were originally described with the
disorder called ‘epilepsy with mental retardation limited to
females’ (eFMR)27. this disorder is characterized by seizure
onset in infancy or early childhood (6-36 months) and cognitive
impairment. the disorder is X-linked with an unusual expression
pattern and with the phenotype being restricted to females;
carrier males remain apparently unaffected, with normal
cognitive function.
Dravet-like syndrome caused by PCDH19 mutations and and
SCN1A mutation-associated Dravet syndrome patients share
several features28. these include normal development before
seizure onset, early onset of seizures (before age one year),
association of febrile and afebrile seizures, with a high
susceptibility of the seizures to being triggered by fever,
occurrence of hemiclonic or unilateral seizures, and later
generalized tonic-clonic seizures, seizures occurring in clusters,
prolonged seizures, and ultimately development of psychomotor
regression. the PCDH19 mutation affected patients however,
present with a later mean age of onset (nine months compared
with six months), fewer absence and myoclonic seizures, and the
condition carries a slightly better developmental outcome. Also
photosensitivity, which is very common in Dravet syndrome, is
unusual in PCDH19 patients.
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the appropriate diagnosis of Dravet syndrome is important as
it has therapeutic implications. Lamotrigine, phenytoin,
carbamazepine, and vigabatrin may worsen the seizures, and
their use should be avoided. treatments with a beneficial effect
include sodium valproate, stiripentol, topiramate, benzodiazepines, and the ketogenic diet29.
Clinical evaluation
encephalopathy

of

an

infant

with

epileptic

the evaluation begins with a detailed history, which should
include details of the pregnancy, delivery and postnatal factors.
History of excessive fetal movements must be elicited; these
could signify the presence of fetal seizures, which are seen in
pyridoxine dependency30. Intra-uterine onset of seizures has also
been described in KCNQ2 epileptic encephalopathy12. A history
of prematurity is common in pyridoxal phosphate responsive
seizures30. the age of onset of the seizures, the type of seizures
and relationship with the sleep wake cycle provide additional
help in seizure and syndrome classification. History of excessive
irritability and vomiting, multisystem symptoms are also
frequently reported in pyridoxine dependency. the sex of the
child is also important, as epileptic encephalopathies associated
with CDKL-5 mutations, and PCDH19 mutations are seen in
girls, while the ones associated with ARX mutations are seen in
boys. However, recently mutations in the CDKL-5 gene have
been described in epileptic encephalopathy in boys as well31. A
detailed family history and a three-generation pedigree should be
constructed.
A history of seizures being precipitated by fever is
characteristic in patients with Dravet syndrome and PCDH19
related mutations. the developmental history is important to
elucidate the pattern of development prior to the onset of
seizures (normal or pre-existing developmental delay).
Information about developmental arrest or regression after the
onset of seizures is of critical importance. the presence of
autistic features and hand stereotypies (Rett like phenotype) is
seen in epileptic encephalopathy associated with CDKL-5
mutations32. the presence of other neurological problems such
as stiffness, vision and hearing problems must be screened for.
A general physical examination must be performed to
look for craniofacial dysmorphic features (chromosomal
abnormalities, peroxisomal disorders, abnormal fat pads in
congenital disorders of glycosylation), and neurocutaneous
markers such as ash leaf macules, which are characteristic of
tuberous sclerosis. Presence of ambiguous genitalia in a child
with infantile spasms is an indication to screen for ARX
mutations19.
the neurological examination must be performed to assess
tone abnormalities, and associated movement disorders such as
dystonia, choreoathetosis, and stereotypies. the presence of
dystonias and progressive spasticity in a child with infantile
spasms may be a clue towards an underlying ARX mutation33.
the ocular fundi must be examined for the presence of
chorioretinitis and or changes of a pigmentary retinopathy, optic
atrophy, which may point towards the presence of infantile
neuronal ceroid lipo-fuchsinosis, and mitochondriopathies.
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Investigations

Investigation of a child with a suspected epileptic
encephalopathy begins with an eeG. A video-eeG is preferable
over a routine eeG, especially if there are very frequent
seizures. A sleep and awake record must be obtained, lasting 4560 minutes, in order not to miss abnormalities. Some
abnormalities such as burst suppression pattern in early
myoclonic encephalopathy and hypsarrhythmia may change
with the sleep wake cycle, hence both states must be sampled.
Photic stimulation must be done, as it is frequently elicits
abnormal photoparoxysmal responses in Dravet syndrome and
infantile neuronal ceroid lipofuchsinosis.
the inter-ictal eeG can be diagnostically useful in Ohtahara
syndrome, early myoclonic encephalopathy, and West syndrome.
However, in Dravet syndrome, the eeG performed during the
first year of life is usually normal. the eeG shows generalized
spike and polyspike wave discharges from two to five years-ofage.
A video-eeG defines and clarifies seizure semiology, and can
identify persistent focal features that may point towards
potentially surgically remediable causes, and will establish
whether many paroxysmal events (which are common in these
children) are seizures, or non-epileptic movements. At times, a
particular seizure semiology may be of diagnostic value; for
instance, a distinct seizure type, the hypermotor-tonic-spasms
sequence has been described in association with CDKL5
mutations34.
A neuroimaging study, preferably an MRI of brain, must be
performed in all children with epileptic encephalopathy.
Magnetic resonance imaging is often diagnostic for brain
malformations, tuberous sclerosis, perinatal insult sequelae such
as asphyxia, while an MR spectroscopy performed
simultaneously can be of diagnostic value in patients with inborn
errors of metabolism (glycine encephalopathy, creatine
deficiency syndromes), and mitochondriopathies (elevated
lactate). Genetic epileptic encephalopathies associated with ARX
mutations may have brain malformations such as
hydranencephaly, lissencephaly (more severe in the posterior
regions), or agenesis of the corpus callosum19. Severe cerebral
hypomyelination has been seen in West syndrome associated
with SPTAN1 mutations21. However, in the majority of the
genetic epileptic encephalopathies, the MRI is normal or may
show non-specific features such as cerebral atrophy or delayed
myelination. the presence of a cortical dysgenesis should not
preclude a genetic or metabolic etiology as is increasingly being
recognized.
Chromosomal karyotyping must be performed if dysmorphic
features are present. If no clue has been found by clinical
evaluation, and neuroimaging, metabolic etiology must be
looked for, especially keeping in mind treatable conditions. If the
initial metabolic investigations exclude hypoglycemia,
hypocalcemia, hypomagnesemia, elevations of lactate and
ammonia, the focus of investigation and management should
continue to vigorously search for treatable epileptic
encephalopathies. Methylene tetrahydrofolate reductase and
biotinidase deficiency must be screened for35. A cerebrospinal
fluid (CSF) examination must be performed to look for low
glucose levels and low CSF to serum glucose ratio (glucose
transporter defect), elevated lactate (mitochondriopathies),
13
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elevated glycine (non-ketotic hyperglyciemia), serine (serine
biosynthesis defects), or pipecolic acid (pyridoxine dependency),
and neurotransmitters (abnormalities seen in Pyridoxal
phosphate dependency)36.
Some authorities recommend a sequential therapeutic trial
with vitamin b6, pyridoxal phosphate and folinic acid should be
instituted early in all babies with epileptic encephalopathy and
poor response to antiepileptic treatment. the reader is referred to
a recent article on the metabolic evaluation and management of
pyridoxine dependent epilepsy (antiquitin deficiency) for
rationale and additional details36.
A protocol for targeted and selective genetic testing can be
developed based on the clinical characteristics of epileptic
encephalopathy and the seizure phenotype, and a syndromic
diagnosis. In this context, the decision and selection of genetic
testing is guided by several principles that take into account the
many ramifications of a particular clinical scenario37. these
principles have been discussed in the document produced by the
ILAe genetics commission38. In the examples discussed where
the gene defect is known, a targeted mutation analysis would
carry great clinical utility as pointed out in the commission
document. the various epileptic syndromes associated with
genetic mutations and their clinical characteristics are detailed in
table 2. testing of SCN1A mutations must be done in patients
with Dravet syndrome. In girls with suspected Dravet syndrome,
if SCN1A mutations are not present, testing for PCDH19
mutations should be performed. testing for SCN1A mutations

may also be considered in children with migrating partial
seizures of infancy, and severe infantile multifocal epilepsy14, 39.
In babies with Ohtahara syndrome, early myoclonic
encephalopathy, and non-syndromic neonatal onset epileptic
encephalopathies, testing for STXBP1 mutations must be
performed, once brain malformations or inherited metabolic
defects have been excluded40. there will be an ensuing debate as
to whether molecular testing should precede screening for
metabolic disorders. the costs of molecular diagnostics under
current conditions would favor the exclusion of structural brain
malformations and treatable metabolic disorders first.
In children with West syndrome with detected etiology,
testing for CDKL-5 mutations must be considered in girls with
early onset seizures, autistic features, and hand stereotypies.
ARX mutations must be tested in the presence of X-linked
inheritance, and/or ambiguous genitalia.
In instances where no definite syndromic diagnosis is made
or the targeted testing excludes the known gene defects, further
genetic testing and its diagnostic yield remains unclear. this
involves testing for copy number variations by single nucleotide
polymorphism (SNP) microarray, genomic imbalances using
array comparative genomic hybridization (CGH)41 and evolving
3rd generation high throughput sequencing technologies using
exome sequencing41. Chromosomal microarray (arrayCGH) is
now recommended as a first-tier test in patients with unexplained
developmental delay, intellectual disability, autism spectrum
disorders, or multiple congenital anomalies42. there is emerging

Table 2: Clinical features and epilepsy syndromes associated with genetic epileptic encephalopathies
Mutation

Associated Epilepsy syndromes

Chief Clinical characteristics

CDKL-5

West syndrome, typical seizure typehypermotor-tonic-spasms

Affects girls, onset between 1-10 weeks of life, autistic features, hand
stereotypies, developmental delay, motor dyspraxia

ARX

West syndrome, Ohtahara syndrome,
myoclonic epilepsy

Affects males, developmental delay, intractable seizures, and
ambiguous genitalia, brain malformations may be associated.

STXBP-1

Ohtahara syndrome, West syndrome,
, non-syndromic early onset epileptic
encephalopathy

Early onset seizures, typically frequent epileptic spasms, developmental
delay

SLC25A22

Ohtahara syndrome

Epileptic spasms and focal seizures associated with suppression burst
beginning in the first days of life, microcephaly, hypotonia

KCNQ2

Epileptic encephalopathy in the
neonatal period and early infancy

Occurrence of intractable seizures in the first week of life with a
prominent tonic component. Seizures generally resolve by age 3 years
but the children are left with severe, intellectual disability and motor
impairment.

SCN1A

Dravet syndrome, migrating partial
seizures of infancy, severe multifocal
epilepsy of infancy

Occurrence of generalized or unilateral clonic or tonic–clonic seizures,
usually triggered by fever, in infancy. Later, other types of seizures
occur, including myoclonus, atypical absences and partial seizures

PCDH 19

Dravet syndrome, Epilepsy with
mental retardation limited to females
(EFMR)

Same as SCN1A associated Dravet syndrome, Affects girls, Implicated
in X-linked mental retardation with epilepsy in girls

(ARX- Aristaless-Related Homeobox Gene, CDKL-5- Cyclin-Dependent Kinase-Like 5 gene, SLC25A22- Solute carrier family 25 member 22 gene, STXBP1- Syntaxin binding protein 1 gene, SCN1A- Sodium channel neuronal type 1a
subunit gene, PCDH19- Protocadherin 19 gene )
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data on the role of copy number variations in epileptic
encephalopathies43,44. In a recent study, out of 315 patients with
epileptic encephalopathies, 7.9 % were found to have rare copy
number variations43. However, molecular karyotyping methods
are yet to find widespread clinical application and utility in the
field of epileptic encephalopathies. this field is rapidly evolving
and will continue to generate additional susceptibility genes of
interest44.
CONCLUSION

epileptic encephalopathies in infants and young children are
caused by structural brain malformations, acquired brain insults,
and inborn errors of metabolism in the majority of the affected
patients. However no cause can be identified in a significant
number of children. Recent advances in molecular diagnostics
have led to the discovery of a number of genetic defects that may
be causative in many epileptic encephalopathies. Most of these
disorders are relatively rare and it will be a while before
sufficient testing and experience will be available to formulate
evidence-based guidelines. Identification of the causative
mutation is important for prognostication and genetic
counseling, and as has been discussed, provides a sound basis for
treatment decisions and symptom management. Knowledge of
the clinical profile, seizure types, and eeG features of the
disease phenotype associated with the specific mutation as
described above help the clinician improve diagnostic precision
and management. Over time, large scale studies involving
multicenter databases and rare disorder registries may capture
the relative prevalence of these rare disorders in populations to
provide evidence based data to make informed decisions.
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